勁方醫藥科技（上海）股份有限公司 董事會審計委員會工作細則 第一章 總則 2 第七條 審計委員會任期與董事會一致，委員任期屆滿，連選可以連任。期 間如有委員不再擔任公司董事職務，自動失去委員資格，並由委員 會根據上述第四至第六條規定補足委員人數。 第八條 董事會須對審計委員會成員的獨立性和履職情況進行定期評估，必 要時可以更換不適合繼續擔任的成員。公司現有核數公司的前任合 夥人在以下日期（以兩者中較後的日期為準）起計兩年期間內，不得 擔任審計委員會的成員：(a)其終止成為該公司合夥人的日期；或(b) 其不再享有該公司任何財務利益的日期。 第九條 審計委員會的職責包括以下方面： （一） 監督及評估外部審計機構工作； （二） 審閱公司的財務資料； （三） 評估內部控制的有效性； （四） 協調管理層及相關部門與外部審計機構的溝通； （五） 公司董事會授權的其他事宜及相關法律法規中涉及的其他 事項。 第十條 審計委員會監督及評估外部審計機構工作的職責須至少包括以下方 面： （一） 就外聘核數師的委任、重新委任及罷免向董事會提供建 議，就批准外聘核數師的薪酬及聘用條款提供建議，以及 處理任何有關核數師辭職或辭退核數師的 ...

勁方醫藥科技（上海）股份有限公司 章程 1 | 目錄 | | --- | | 第一章 | 總則 | 3 | | --- | --- | --- | | 第二章 | 經營宗旨和範圍 | 4 | | 第三章 | 股份 | 4 | | 第一節 | 股份發行 | 4 | | 第二節 | 股份增減和回購 | 8 | | 第三節 | 股份轉讓 | 9 | | 第四章 | 股東和股東會 | 10 | | 第一節 | 股東 | 10 | | 第二節 | 股東會的一般規定 | 16 | | 第三節 | 股東會的召集 | 18 | | 第四節 | 股東會的提案與通知 | 19 | | 第五節 | 股東會的召開 | 21 | | 第六節 | 股東會的表決和決議 | 24 | | 第五章 | 董事會 | 29 | | 第一節 | 董事 | 29 | | 第二節 | 董事會 | 32 | | 第六章 | 高級管理人員 | 36 | | 第七章 | 監事會 | 37 | | 第一節 | 監事 | 37 | | 第二節 | 監事會 | 38 | | 第八章 | 財務會計制度、利潤分配和審計 | 40 | | 第一節 | 財務會計制度 | ...

Group 1 - The core viewpoint of the news is that Jinfang Pharmaceutical-B (02595) has successfully conducted an oversubscribed IPO, raising significant capital for its clinical development projects [1][2] - The company recorded a total subscription of HKD 349.85 billion, with the public offering portion being oversubscribed by 2,210 times [1] - Jinfang Pharmaceutical plans to issue 77.6 million H-shares at a price of HKD 20.39 per share, aiming to raise HKD 1.58 billion [1] Group 2 - The company focuses on developing new treatment solutions for oncology, autoimmune, and inflammatory diseases, with a product pipeline that includes eight candidate products [1][2] - Two core products, GFH925 and GFH375, are in clinical development, with GFH925 already commercialized in China for treating advanced non-small cell lung cancer (NSCLC) [1][2] - The net proceeds from the IPO will be allocated as follows: approximately 33% for the clinical development of GFH925, 38% for GFH375, 19% for other candidate products, and 10% for general corporate purposes [2]

Core Insights - The company, Jinfang Pharmaceutical-B (02595), conducted an IPO from September 11 to 16, raising significant interest with a subscription amount of HKD 349.85 billion, resulting in an oversubscription rate of 2,210 times for the public offering portion [1] - The company plans to issue 77.6 million H-shares at a price of HKD 20.39 per share, aiming to raise HKD 1.58 billion, with the shares expected to be listed in Hong Kong on September 19 [1] - Jinfang Pharmaceutical focuses on developing new treatment solutions for oncology, autoimmune, and inflammatory diseases, with a product pipeline that includes eight candidate products, five of which are in clinical development [1][2] Financial Details - The net proceeds from the IPO will be allocated as follows: approximately 33% for the clinical development of core product GFH925, about 38% for core product GFH375, around 19% for the development of other candidates in the pipeline, and about 10% for working capital and general corporate purposes [2] Product Pipeline - Core product GFH925 (fulzerasib, marketed as Daberet®) has been commercially approved in China for the treatment of advanced non-small cell lung cancer (NSCLC) and is currently undergoing Phase II trials in the EU [1] - Another core product, GFH375, is an oral small molecule inhibitor targeting KRAS G12D mutations, with ongoing Phase I/II clinical trials in China for patients with advanced solid tumors carrying this mutation [2]

Group 1 - The core viewpoint of the news is that two companies, Jinfang Pharmaceutical-B (02595) and Different Group (06090), are currently in the process of public offering, with significant oversubscription levels reported [1] Group 2 - Jinfang Pharmaceutical-B has received a total of HKD 219.64325 billion in borrowings from various brokers, with an oversubscription rate exceeding 1389 times [1][2] - Different Group has secured HKD 9.3389 billion in borrowings, with an oversubscription rate exceeding 10.9 times [1][2] Group 3 - The total fundraising amount for Jinfang Pharmaceutical-B is HKD 1.58 billion [2] - The total fundraising amount for Different Group is HKD 0.78 billion [2]

Group 1: Company Overview - Company name:劲方医药-B, established in 2017, focuses on innovative drug development for oncology, autoimmune, and inflammatory diseases [8][10] - The company has a product pipeline consisting of 8 candidate products, with 5 in clinical development, including core products GFH925 and GFH375 [10][12] - GFH925 is the first KRAS G12C inhibitor approved for commercialization in China, while GFH375 is a KRAS G12D inhibitor currently in clinical trials [12][16] Group 2: IPO Details - The IPO is scheduled from September 11 to September 16, with a listing date on September 19, at a price of HKD 20.39 per share [3][4] - The total fundraising amount is HKD 15.82 billion, with a total issuance of 77,600,000 shares, of which 10% is for public offering and 90% for international placement [3][4] - The company has a strong cornerstone investor base, with 9 investors committing USD 100 million, accounting for 49.27% of the total issuance [5] Group 3: Financial Performance - Revenue for 2023, 2024, and the first four months of 2025 is projected at RMB 73.74 million, RMB 104.70 million, and RMB 82.15 million respectively [18][22] - The company has been operating at a loss, with net profits of -RMB 508.32 million, -RMB 677.64 million, and -RMB 66.62 million for the respective periods [19][22] - As of April 30, 2025, the company has cash reserves of RMB 391 million [21] Group 4: Market and Competitive Landscape - The global KRAS G12C inhibitor market is expected to grow from USD 489 million in 2024 to USD 3.491 billion by 2033, with a compound annual growth rate of 24.4% [13][16] - The competitive landscape includes several approved KRAS G12C inhibitors, with GFH925 being the first in China and competing against products from major pharmaceutical companies [16] - The company aims to expand its product pipeline beyond RAS drugs, including candidates like GFS202A, a bispecific antibody targeting GDF15 and IL-6 [16][17]

Core Viewpoint - Jinfang Pharmaceutical-B (02595) is currently in the process of an IPO, with significant oversubscription indicating strong investor interest [1] Group 1: IPO Details - As of September 12, a total of HKD 379.8185 billion has been lent by brokers including Futu, Huatai, and others for Jinfang Pharmaceutical-B's IPO, resulting in an oversubscription of over 239 times [1][2] - The total amount raised from the IPO is HKD 1.58 billion [2] Group 2: Broker Contributions - Futu contributed HKD 187.90 billion, while Huatai contributed HKD 65.00 billion [2] - Other brokers such as Ruch, Xincheng, and Yaocai also participated, with smaller contributions totaling HKD 79.4789 billion [2]

Group 1 - Health 160 (02656) and Jinfang Pharmaceutical-B (02595) are currently in the process of public offering, with significant oversubscription levels reported [1] - As of September 11, a total of HKD 89.9819 billion has been borrowed by brokers for Health 160, resulting in an oversubscription of over 178 times [1][2] - For Jinfang Pharmaceutical-B, brokers have borrowed HKD 92.9193 billion, leading to an oversubscription of over 57.8 times [1][2] Group 2 - The total amount raised for Health 160 is HKD 0.5 billion, while Jinfang Pharmaceutical-B has raised HKD 1.58 billion [2] - Major brokers involved in the borrowing for Health 160 include Futu, Huatai, and Yaocai, with Futu contributing HKD 41.75 billion [2] - For Jinfang Pharmaceutical-B, the largest contributions come from Futu and Huatai, amounting to HKD 52.90 billion and HKD 17.00 billion respectively [2]

Core Insights - The company, Jingfang (02595.HK), is a biopharmaceutical firm focused on developing new treatment solutions for tumors, autoimmune, and inflammatory diseases, with a pipeline of eight candidate products, five of which are in clinical development [3][4] Company Overview - Jingfang's core product, GFH925 (fulzerasib), is a newly discovered drug that has received commercial approval in China for treating advanced non-small cell lung cancer (NSCLC), making it the first approved selective KRAS G12C inhibitor in China and the third globally [3][4] - The company is conducting an ongoing Ib/II clinical trial (KROCUS trial) in EU countries to evaluate the potential of GFH925 in combination with cetuximab as a first-line treatment for advanced NSCLC [4] Clinical Development Plans - Jingfang plans to leverage clinical results obtained in Europe to apply for a Phase III clinical trial in the US and Europe, having held an IND pre-meeting with the FDA in February 2025, with plans to initiate the Phase III trial in Q4 2025 [4] - GFH375, an oral bioavailable small molecule inhibitor targeting KRAS G12D, has initiated a Phase I/II clinical trial in China for patients with advanced solid tumors carrying the KRAS G12D mutation, with a key clinical trial expected to start in Q4 2025 [4] Market Potential - The global market for KRAS G12C inhibitors for treating NSCLC is projected to grow from $90 million in 2021 to $464.7 million by 2024, with a compound annual growth rate (CAGR) of 72.8%, and is expected to reach $2.7576 billion by 2033, with a CAGR of 21.9% from 2024 [5] - The market for KRAS G12C inhibitors for treating colorectal cancer (CRC) is expected to grow from $24.5 million in 2024 to $733 million by 2033, with a CAGR of 45.9% starting in 2024 [5] - In the Greater China region, the market for KRAS G12C inhibitors for treating NSCLC is anticipated to grow from $13.1 million in 2024 to $559.8 million by 2033, with a CAGR of 51.7% from 2024 [5]

獨家保薦人、獨家保薦人兼整體協調人、聯席全球協調人、 聯席賬簿管理人及聯席牽頭經辦人 勁方醫藥科技 ( 上海 ) 股份有限公司 GenFleet Therapeutics (Shanghai) Inc. 股份代號 : 2595 （於中華人民共和國註冊成立的股份有限公司） 全球發售 重要提示 重要提示：閣下如對本招股章程的任何內容有任何疑問，應尋求獨立專業意見。 GenFleet Therapeutics (Shanghai) Inc. 勁 方 醫 藥 科 技（ 上 海 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） 全球發售 | 全球發售的發售股份數目 | ： | 77,600,000股H股（視乎發售量調整權 | | --- | --- | --- | | | | 及超額配股權行使與否而定） | | 香港發售股份數目 | ： | 7,760,000股H股（可予重新分配） | | 國際發售股份數目 | ： | 69,840,000股H股（可予重新分配及 | | | | 視乎發售量調整權及超額配股權 | | | | 行使與否而定） | | 發售價 | ： | 每股發售股份20.39港元，另加 ...